Michael Gal

Michael Gal

Auto-generated profile, based on publicly available information

Michael Gal

Shaare Zedek Med Ctr, Dept Obstet & Gynecol, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2006 in Human Reproduction
Verified
Journal Article
Open access
PDF file
EME.J. Margalioth
E.J. Margalioth
ABA. Ben-Chetrit
A. Ben-Chetrit
MGM. Gal
M. Gal
TET. Eldar-Geva
T. Eldar-Geva
Pregnancy rate following one cycle of IVF and ET can be as high as 60%. But even in the very successful units, some couples fail repeatedly. The causes for repeated implantation failure (RIF) may be because of reduced endometrial receptivity, embryonic defects or multifactorial causes. Various uterine pathologies, such as thin endometrium, altered expression of adhesive molecules and immunological factors, may decrease endometrial receptivity, whereas genetic abnormalities of the male or female, sperm defects, embryonic aneuploidy or zona hardening are among the embryonic reasons for failure of implantation. Endometriosis and hydrosalpinges may adversely influence both. In this mini review, we discuss the suggested methods for evaluation and treatment of RIF: repeated hysteroscopy, myomectomy, endometrial stimulation, immunotherapy, preimplantation genetic screening (PGS), assisted hatching, zygote intra-Fallopian transfer (ZIFT), co-culture, blastocyst transfer, cytoplasmic transfer, tailoring stimulation protocols and salpingectomy for hydrosalpinges.

19 August 2005 in Human Reproduction
Verified
Journal Article
Open access
PDF file
TETalia Eldar-Geva
Talia Eldar-Geva
ABAvraham Ben-Chetrit
Avraham Ben-Chetrit
ISIrving M. Spitz
Irving M. Spitz
RRRon Rabinowitz
Ron Rabinowitz
EMEinat Markowitz
Einat Markowitz
EMEhud J. Margalioth
Ehud J. Margalioth
BACKGROUND: We evaluated basal and dynamic hormonal markers [(FSH, inhibin B, estradiol and anti-Mullerian hormone (AMH)] during the follicular phase and luteal phase of the menstrual cycle and ultrasonic ovarian morphology as predictors of IVF outcome. METHODS: Fifty-six women, aged <38 years, with normal day 3 FSH levels were included prospectively. Serum estradiol, inhibin B and AMH were measured before and 24 h after administration of 300 IU of recombinant FSH on cycle day 3–4 and during the luteal phase. Ovarian volume and antral follicle count (AFC) were evaluated on cycle day 3–4. The predictive value of oocyte number and pregnancy were assessed using uni- and multivariate analysis. RESULTS:Poor responders (20 oocytes) had significantly higher AFC, AMH and luteal stimulated inhibin B and estradiol than normal responders. Multivariate regression analyses showed that the best models for predicting oocyte number included AFC, follicular phase AMH and stimulated inhibin B. Only AMH showed a significant difference between pregnant and non-pregnant women at both cycle phases. CONCLUSIONS: In young women (<38 years), AFC or basal AMH and stimulated inhibin B predict ovarian response for IVF. The only predictor for pregnancy is follicular or luteal phase AMH.

26 January 2006 in Human Reproduction
Verified
Journal Article
Open access
PDF file
RBRachel Babayof
Rachel Babayof
EMEhud J. Margalioth
Ehud J. Margalioth
Mahmoud HuleihelMahmoud Huleihel
Mahmoud Huleihel
AAAlaa Amash
Alaa Amash
EZEdit Zylber-Haran
Edit Zylber-Haran
TETalia Eldar-Geva
Talia Eldar-Geva
BACKGROUND: We aimed to examine the serum levels of inhibin A, vascular endothelial growth factor (VEGF), tumour necrosis factor α (TNFα), estradiol (E2) and progesterone levels after triggering of final oocyte maturation with GnRH agonist compared with HCG in patients with polycystic ovaries (PCO) and to investigate the relationship between these markers and ovarian hyperstimulation syndrome (OHSS). METHODS: Twenty-eight patients with PCO, undergoing controlled ovarian hyperstimulation with FSH and GnRH antagonist for IVF–embryo transfer treatment, were randomized for triggering of final oocyte maturation with GnRH agonist (GnRH agonist group, n = 15) or HCG (HCG group, n = 13). Blood samples were obtained on the day of randomization and thereafter every 2–7 days. Serum levels of inhibin A, VEGF, TNFα, E2 and progesterone, the incidence of OHSS, ovarian size and pelvic fluid accumulation were evaluated. RESULTS: Serum inhibin A, E2 and progesterone levels were significantly lower in the GnRH agonist group compared with the HCG group, particularly on the day of embryo transfer (P < 0.0001). Serum VEGF and TNFα levels were similar between the two groups. Four patients in the HCG group developed severe OHSS, whereas no patient had any symptoms or signs of OHSS in the GnRH-agonist group (P < 0.05). CONCLUSIONS: In patients with PCO treated with FSH/GnRH antagonist, final oocyte maturation with GnRH agonist instead of HCG reduces significantly inhibin A, E2 and progesterone levels during the luteal phase. This phenomenon reflects the inhibition of the corpus luteum function and may explain, at least in part, the mechanism of OHSS prevention in high-risk patients. Our results do not support a crucial role for VEGF or TNFα in OHSS.

31 March 2005 in Human Reproduction
Verified
Journal Article
Open access
PDF file
TETalia Eldar-Geva
Talia Eldar-Geva
EMEhud J. Margalioth
Ehud J. Margalioth
MGMichael Gal
Michael Gal
ABAvraham Ben-Chetrit
Avraham Ben-Chetrit
NANurit Algur
Nurit Algur
ISIrving M. Spitz
Irving M. Spitz
BACKGROUND: Anti-Mullerian hormone (AMH) is expressed in pre- and small-antral follicles. High serum levels are found in women with polycystic ovaries (PCO), accordant with their increased content of small follicles. To evaluate the relationship between AMH, folliculogenesis and hyperandrogenism, we compared serum AMH levels between women with PCO with and without hyperandrogenism and normal controls during controlled ovarian hyperstimulation (COH). METHODS: Nineteen women with PCO and hyperandrogenism (group A), 10 women with PCO but no hyperandrogenism (group B) and 23 ovulatory women with normal ovarian morphology (group C, controls) underwent COH with the long protocol. Serum levels of AMH, estradiol, androstenedione and follicular tracking were determined before gonadotropins treatment (day 0) and every 2–4 days up to the day of HCG administration. RESULTS: AMH levels declined gradually throughout COH in the three groups, but remained higher in groups A and B compared with the controls. Significantly higher levels were found in group A compared with group B, despite comparable numbers of small follicles. Multiple regression analysis revealed that both the number of small follicles and serum androgens were correlated to AMH. CONCLUSIONS: Women with PCO have higher serum AMH levels during COH than controls. Hyperandrogenism is associated with an additional increase in AMH. It is conceivable that hyperandrogenism may reflect more severe disruption of folliculogenesis in women with PCO or may affect AMH secretion.

1 December 2006 in Fertility and Sterility
Verified
Journal Article
Closed access
ITIlan Tur-Kaspa
Ilan Tur-Kaspa
MGMichael Gal
Michael Gal
MHMichael Hartman
Michael Hartman
JHJason Hartman
Jason Hartman
AHAlex Hartman
Alex Hartman

1 June 2003 in Fertility and Sterility
Verified
Journal Article
Closed access
TETalia Eldar-Geva
Talia Eldar-Geva
BBBaruch Brooks
Baruch Brooks
EMEhud J Margalioth
Ehud J Margalioth
EZEdit Zylber-Haran
Edit Zylber-Haran
MGMichael Gal
Michael Gal
SSSherman J Silber
Sherman J Silber